Boehringer to expand oncology presence with $572m Tessellate Bio deal
The agreement gives Boehringer access to Tessellate’s novel approach targeting ALT-dependent tumours.
The agreement gives Boehringer access to Tessellate’s novel approach targeting ALT-dependent tumours.
What's Your Reaction?
